| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Men |
| Source | CNN (via ABC17 News) |
| URL | abc17news.com/cnn-health/2026/06/20/what-men-should-know-about-the-us-governments-latest-move-on-testosterone-therapy (opens in a new tab) |
Specific Claim Evaluated
No label changes have been made yet; a trial of more than 5,200 men found no meaningful increase in major cardiovascular events, and therapy requires a clear diagnosis based on symptoms and consistently low testosterone.
Primary Research Supporting or Contradicting the Claim
The FDA requested labeling updates in June 2026 (U.S. Food and Drug Administration, 2026b). TRAVERSE showed noninferiority for major adverse cardiac events (Lincoff et al., 2023), and guidelines require symptoms and repeated low testosterone for diagnosis (Bhasin et al., 2018).
Corrected Evidence-Based Interpretation
The report is correct.
Rationale for Grade
The article states the pending status of the changes, reports the trial result and adverse effects and emphasizes diagnostic requirements.
References
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs" - Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"